Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer
Mené sur 1 607 patientes atteintes d'un cancer du sein de stade pN1 ou pN0 (durée médiane de suivi : 9,6 ans), cet essai randomisé international de phase III évalue l'intérêt, du point de vue de la survie globale, d'une irradiation de la paroi thoracique après mastectomie
In the management of breast cancer, treatment approaches are locoregional (i.e., surgery and radiotherapy) or systemic (i.e., chemotherapy, targeted therapy, endocrine therapy, and immunotherapy). The two approaches and their components relate to and complement each other in a delicate balance, with an improvement in efficacy on one side allowing for a de-escalation or even omission of therapy on the other side. Because oncologic outcomes for patients with breast cancer have improved notably over time, owing mainly to earlier disease detection and improved systemic treatment,1 researchers have embarked on the risk-gauging road of de-escalation of locoregional treatment. The driving force behind . . .
New England Journal of Medicine , éditorial, 2025